European equities traded in the US as American depositary receipts were marginally higher late Monday morning, rising 0.06% to 1,423.70 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biopharmaceutical company Genfit (GNFT) and medical device maker EDAP TMS (EDAP), which rose 12% and 1.8%, respectively. They were followed by financial services company Banco Bilbao Vizcaya Argentaria (BBVA) and biopharmaceutical company DBV Technologies (DBVT), which were up 1.3% and 1.2%, respectively.
The decliners from continental Europe were led by biotech firm BioNTech (BNTX) and biopharmaceutical company Cellectis (CLLS), which fell 3.2% and 1.3%, respectively. They were followed by 3D printer company Materialise (MTLS) and oil and gas company Eni (E), which were down 1.2% and 1%, respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical company NuCana (NCNA), which soared 51%, followed by biopharmaceutical company Adaptimmune Therapeutics (ADAP), which advanced 4.1%. They were followed by oil and gas company BP (BP) and biopharmaceutical company Akari Therapeutics (AKTX), which increased 2.3% and 2.2%, respectively.
The decliners from the UK and Ireland were led by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company Mereo BioPharma Group (MREO), which lost 5.1% and 4.9%, respectively. They were followed by biopharmaceutical company Bicycle Therapeutics (BCYC) and biotech firm Trinity Biotech (TRIB), which dropped 3.9% and 3.6%, respectively.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。